Drug Trial Radar · NCT05650632
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Mar 21, 2023
Primary completion
Aug 2029
Study completion Aug 2029
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Dec 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine adverse events and change in disease symptoms of etentamig (ABBV-383) in adult participants with relapsed/refractory (R/R) MM. Etentamig (ABBV-383) is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study is broken into 4 Arms; Arm A (Parts 1 and 2), Arm B and Arms C \& D. Arm A includes 2 parts: step-up dose optimization (Part 1) and dose expansion (Part 2). In Part 1, different level of step-up doses are tested followed by the target dose of etentamig (ABBV-383). In Part 2, the step-up dose identified in Part 1 (Dose A) will be used followed by the target dose A of etentamig (ABBV-383). In Arm B a flat dose of etentamig (ABBV-383) will be tested. In Arms C \& D, the step-up dose identified in Arm A will be used followed by the target dose of etentamig (ABBV-383) to investigate outpatient administration of etentamig (ABBV-383). In Arm E, etentamig (ABBV-383) will be investigated for outpatient administration. Around 250 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 50 sites across the world. Participants will receive etentamig (ABBV-383) as an infusion into the vein in 28 day cycles for approximately 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.
Conditions
- Multiple Myeloma
Interventions
Etentamig (ABBV-383)Drug
Intravenous Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Arm A (Part 1 and Part 2) Arm C, Arm D, and Arm E: Number of Grade >= 2 Cytokine Release Syndrome (CRS) EventsTime frame: Up to Day 28
- Arm B: Number of Adverse Events (AEs) of Special Interest (CRS and Immune Effector Cell-associated Neurotoxicity Syndrome [ICANS])Time frame: Up to Day 28
Locations
44 sites in 7 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona /ID# 251405
Phoenix, Arizona · Recruiting
Highlands Oncology Group - Springdale /ID# 267742
Springdale, Arkansas · Recruiting
Rocky Mountain Cancer Centers - Aurora /ID# 268574
Aurora, Colorado · Recruiting
Medical Oncology Hematology Consultants /ID# 268560
Newark, Delaware · Recruiting
Hope And Healing Cancer Services /ID# 268536
Hinsdale, Illinois · Recruiting
Fort Wayne Medical Oncology And Hematology /ID# 268179
Fort Wayne, Indiana · Recruiting
Franciscan St. Francis Health /ID# 280928
Indianapolis, Indiana · Recruiting
East Jefferson General Hospital /ID# 251204
Metairie, Louisiana · Recruiting
Mayo Clinic - Rochester /ID# 251164
Rochester, Minnesota · Recruiting
NHO Revive Research Institute, LLC /ID# 267869
Lincoln, Nebraska · Recruiting
Nebraska Cancer Specialists - Omaha - Wright Street /ID# 282497
Omaha, Nebraska · Recruiting
Icahn School of Medicine at Mount Sinai /ID# 251166
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center-Koch Center /ID# 251167
New York, New York · Recruiting
University of North Carolina /ID# 251203
Chapel Hill, North Carolina · Recruiting
Atrium Health Wake Forest Baptist Medical Center /ID# 251165
Winston-Salem, North Carolina · Recruiting
University Of Cincinnati Medical Center /ID# 251746
Cincinnati, Ohio · Recruiting
Willamette Valley Cancer Institute and Research Center /ID# 267088
Eugene, Oregon · Recruiting
Vanderbilt Ingram Cancer Center /ID# 252470
Nashville, Tennessee · Recruiting
Texas Oncology - Central/South Texas /ID# 268563
Austin, Texas · Recruiting
Texas Oncology - Dallas - Worth Street /ID# 280064
Dallas, Texas · Recruiting
Oncology Consultants /ID# 268323
Houston, Texas · Recruiting
Texas Oncology - Northeast Texas /ID# 268877
Tyler, Texas · Recruiting
Virginia Cancer Specialists - Fairfax /ID# 268559
Fairfax, Virginia · Recruiting
Fred Hutchinson Cancer Center - Seattle - Eastlake Avenue East /ID# 267940
Seattle, Washington · Recruiting
Northwest Medical Specialties Tacoma /ID# 267117
Tacoma, Washington · Recruiting
Juravinski Cancer Centre /ID# 252053
Hamilton, Ontario, Canada · Recruiting
Ottawa Hospital Research Institute /ID# 252151
Ottawa, Ontario, Canada · Completed
Odense University Hospital /ID# 251261
Odense, Region Syddanmark, Denmark · Recruiting
Vejle Sygehus /ID# 251260
Vejle, Region Syddanmark, Denmark · Recruiting
AP-HP - Hopital Saint-Antoine /ID# 252326
Paris, France · Completed
Institut Paoli-Calmettes /ID# 252100
Marseille, Bouches-du-Rhone, France · Completed
Hopitaux Universitaires Henri Mondor - Hopital Henri Mondor /ID# 252101
Créteil, Paris, France · Completed
Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 251196
Nantes, Pays de la Loire Region, France · Recruiting
HCL - Hopital Lyon Sud /ID# 251223
Pierre-Bénite, Rhone, France · Recruiting
CHU Poitiers - La miletrie /ID# 251219
Poitiers, Vienne, France · Recruiting
Rabin Medical Center. /ID# 251330
Petah Tikva, Central District, Israel · Recruiting
Hadassah Medical Center-Hebrew University /ID# 252079
Jerusalem, Jerusalem, Israel · Recruiting
The Chaim Sheba Medical Center /ID# 251329
Ramat Gan, Tel Aviv, Israel · Recruiting
Tel Aviv Sourasky Medical Center /ID# 251573
Tel Aviv, Tel Aviv, Israel · Recruiting
Hospital Universitario de Salamanca /ID# 251529
Salamanca, Spain · Recruiting
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.